A composition of matter including two optionally substituted phenol or optionally substituted aniline units separated by a furan spacer has been prepared. In particular, the chemical structure has a novolac bridge between the central furan ring and the two attached optionally substituted phenol and/or optionally substituted aniline units. These compounds can be modified to be used in various polymer resins. This new structure reduces toxicity relative to BPA/F, makes use of renewable chemicals, and produces certain beneficial polymer properties.

A composition of matter including two optionally substituted phenol or optionally substituted aniline units separated by a furan spacer has been prepared. In particular, the chemical structure has a novolac bridge between the central furan ring and the two attached optionally substituted phenol and/or optionally substituted aniline units. These compounds can be modified to be used in various polymer resins. This new structure reduces toxicity relative to BPA/F, makes use of renewable chemicals, and produces certain beneficial polymer properties.

The present specification relates to a heterocyclic compound of Chemical Formula 1, and an organic light emitting device comprising the same. The heterocyclic compound as a material of an organic material layer of the organic light emitting device provides enhanced efficiency, low driving voltage and increased lifetime. ##STR00001##

The present specification relates to a heterocyclic compound of Chemical Formula 1, and an organic light emitting device comprising the same. The heterocyclic compound as a material of an organic material layer of the organic light emitting device provides enhanced efficiency, low driving voltage and increased lifetime. ##STR00001##

The present disclosure provides a compound of Formula (I′): ##STR00001## or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R.sub.x, X.sub.1, X.sub.2, and R.sub.1 are as defined herein, and methods of making and using same.

The present disclosure provides a compound of Formula (I′): ##STR00001## or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R.sub.x, X.sub.1, X.sub.2, and R.sub.1 are as defined herein, and methods of making and using same.

Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 to R.sup.4, R.sup.7 to R.sup.10, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. ##STR00001##

Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: ##STR00001## wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: ##STR00001## wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.